How best to treat Addison's disease in dogs?

Carr, Anthony P.

doi:10.1136/vr.i4052

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fludrocortisone has a half-life of approximately 11 hours in dogs 16 ; for treatment of PH, it is administered orally once or twice daily. 17 It has been suggested that, when changing dogs from treatment with fludrocortisone to treatment with DOCP and a glucocorticoid, fludrocortisone treatment should be continued following the first administration DOCP, and then gradually tapered down over a few days. 18 In this trial, fludrocortisone was discontinued immediately before DOCP administration in all 44 dogs which had been previously treated with fludrocortisone.…”

Section: Discussionmentioning

confidence: 99%

Randomised clinical non‐inferiority trial comparing two formulations of desoxycortone pivalate for the treatment of canine primary hypoadrenocorticism

Farr¹,

Mason²,

Longhofer³

2020

Veterinary Record

View full text Add to dashboard Cite

BackgroundThis clinical trial compared two formulations of desoxycortone pivalate (DOCP) for treating the mineralocorticoid deficit in dogs with primary hypoadrenocorticism (PH).MethodsAt veterinary clinics in the USA and France, dogs with PH (n=152) were randomised (3:1) to receive approximately monthly treatments with either the test product, Zycortal (Dechra), administered subcutaneously (n=113), or the control product, Percorten-V (Novartis Animal Health), administered intramuscularly (n=39), both at an initial dose of 2.2 mg/kg DOCP. Treatment administrators were unblinded; veterinarians assessing clinical signs were blinded; owners were blinded until at least day 90, the primary end point. Veterinarians assessed treatment outcome based on all of the following: clinical signs; sodium concentrations; potassium concentrations. Dogs received concurrent glucocorticoid therapy throughout the trial. Non-inferiority was assessed using a generalised linear mixed model to compare success rates between groups.ResultsSuccess rates at day 90 were similar between groups (per-protocol population at day 90: Zycortal 87/101, 86.2 per cent, Percorten-V 29/34, 85.1 per cent). Zycortal was non-inferior to Percorten-V as the upper limit of the 95 per cent CI for the difference between groups was 13.6 per cent. Polydipsia and polyuria were the most common clinical observations.ConclusionBoth products, in combination with glucocorticoid therapy, were safe and effective in treating PH.

show abstract

Section: Discussionmentioning

confidence: 99%